Equities

Creative Medical Technology Holdings Inc

CELZ:NAQ

Creative Medical Technology Holdings Inc

Actions
FinancialsInvestment Banking and Brokerage Services
  • Price (USD)3.12
  • Today's Change0.01 / 0.32%
  • Shares traded93.25k
  • 1 Year change-39.42%
  • Beta5.0406
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Creative Medical Technology Holdings Inc share price to rise to 30.00 in the next year from the last price of 3.12.
High861.5%30.00
Med861.5%30.00
Low861.5%30.00

Earnings history & estimates in USD

On Aug 09, 2024, Creative Medical Technology Holdings Inc reported 2nd quarter 2024 losses of -1.11 per share.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate-15.21%
Creative Medical Technology Holdings Inc reported annual 2023 losses of -3.76 per share on Mar 22, 2024.
Average growth rate+59.57%
More ▼

Revenue history & estimates in USD

Creative Medical Technology Holdings, Inc. had 2nd quarter 2024 revenues of 8.00k. The one analyst following the company did not expect it to generate revenues.
Average growth rate-75.00%
Creative Medical Technology Holdings, Inc. had revenues for the full year 2023 of 9.00k. This was 89.89% below the prior year's results.
Average growth rate-44.38%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.